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Abstract
Background: Rapid progress over the past decade has been made with the development of the ‘Artificial Pancreas’, also
known as the closed-loop system, which emulates the feedback glucose-responsive functionality of the pancreatic beta
cell. The recent FDA approval of the first hybrid closed-loop system makes the Artificial Pancreas a realistic therapeutic
option for people with type 1 diabetes. In anticipation of its advent into clinical care, we provide a primer and appraisal of
this novel therapeutic approach in type 1 diabetes for healthcare professionals and non-specialists in the field.
Discussion: Randomised clinical studies in outpatient and home settings have shown improved glycaemic outcomes,
reduced risk of hypoglycaemia and positive user attitudes. User input and interaction with existing closed-loop systems,
however, are still required. Therefore, management of user expectations, as well as training and support by healthcare
providers are key to ensure optimal uptake, satisfaction and acceptance of the technology. An overview of closed-loop
technology and its clinical implications are discussed, complemented by our extensive hands-on experience with closed-
loop system use during free daily living.
Conclusions: The introduction of the artificial pancreas into clinical practice represents a milestone towards the goal of
improving the care of people with type 1 diabetes. There remains a need to understand the impact of user interaction
with the technology, and its implication on current diabetes management and care.
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Background
Glycaemic control with insulin therapy is influenced by
factors such as insulin dosage, absorption and timing [1],
as well as physiological and lifestyle factors such as phys-
ical activity, meal intake, hormones and illness [2–4].
These factors may contribute to the notable variability in
insulin requirements, which makes self-management of
type 1 diabetes challenging [5]. As a result, the majority of
people with type 1 diabetes are still unable to achieve their
recommended therapeutic goals. Therefore, there is cur-
rently an unmet need to improve glycaemic control and
alleviate the risk of hypoglycaemia whilst reducing the
burden of type 1 diabetes self-management.
Currently available technology
The use of continuous glucose monitoring in motivated
individuals has shown improvements in glycaemic control
[6] and complements insulin pump management in the
form of sensor-augmented pump therapy [7]. Advanced
features of sensor-augmented pump therapy have recently
been introduced into clinical practice; this includes auto-
matic suspension of insulin delivery when a pre-set glu-
cose threshold is reached (low glucose suspend) [8] or
predicted to be reached (predictive low glucose suspend)
[9]. Both approaches have shown significant reduction in
the risk and burden of hypoglycaemia, particularly in
hypoglycaemia-prone individuals, with the latter stabilis-
ing glucose levels perhaps due to a reduced need for
supplemental carbohydrates to treat hypoglycaemia often
resulting in rebound hyperglycaemia [9].
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Foundation of the artificial pancreas
Parallel to these relatively simple but progressive ap-
proaches to mitigate the risk of hypoglycaemia, bolder
developments have taken place to link insulin delivery
directly to glucose levels. Closed-loop insulin delivery,
also known as the Artificial Pancreas, differs from
conventional pump therapy and low glucose manage-
ment technology through a control algorithm that aut-
onomously increases and decreases subcutaneous insulin
delivery based on real-time sensor glucose levels (Fig. 1)
[10]. Closed-loop systems can be categorised into
insulin-only and bi-hormonal control systems [11]. The
former achieve target glucose level by modulating insu-
lin delivery alone, whereas the latter utilise both insulin
and glucagon. Manual meal-time announcement and
prandial insulin boluses are still recommended to be
carried out by the user to overcome the delay in insulin
action profile of currently available insulin analogues.
This ‘hybrid’ closed-loop approach is in contrast to a
‘fully’ closed-loop approach, in which user input to the
control algorithm related to meals is not required. The
recent approval of the US Food and Drug Administra-
tion (FDA) of a hybrid closed-loop insulin delivery sys-
tem has been borne by the hope and expectations of
type 1 diabetes community, patient advocacy organisa-
tions and healthcare providers that it may help reduce
the burden of type 1 diabetes management and improve
glycaemic control [12]. This signifies a major advance in
fulfilling regulatory requirements, enabling people with
type 1 diabetes to benefit from this novel technology.
Clinical evidence behind the Artificial Pancreas
Clinical studies have progressed over the past decade
from controlled research facility [13] and supervised
transitional settings [14, 15] to free-living home studies
[16, 17]. Two recent multicentre randomised crossover
free-living home studies evaluated single-hormone hy-
brid closed-loop system use over a longer period in
adults. In one study, 2-month closed-loop use in the
evening, after dinner, and overnight was compared to
sensor-augmented pump therapy [17]. Closed-loop insu-
lin delivery improved the time spent in the target glu-
cose range between 3.9 and 10.0 mmol/L and HbA1c,
and reduced the time spent hypoglycaemic. This was in
line with a 3-month study comparing day-and-night
closed-loop use with sensor-augmented pump therapy
[16], where improvements in time in the target glucose
range, HbA1c and hypoglycaemia were also shown.
Through the modulation of insulin delivery by closed-loop
control algorithm, more consistent glucose levels were
achieved without increasing the total amount of insulin
delivered. The largest clinical study of a hybrid single hor-
mone closed-loop system to date has demonstrated safety
in an outpatient setting over 3 months [18].
Closed-loop application has also been evaluated in other
populations. Closed-loop use in children and adolescents
has shown improvement in either time spent in the glu-
cose target range [19] or reduction in hypoglycaemia risk
[20]. In pregnant women with type 1 diabetes, improve-
ments in time in the glucose target range and mean glu-
cose was achieved by closed-loop without increasing
hypoglycaemia risk compared to sensor-augmented pump
therapy [21].
A number of research groups are currently focussing on
the incremental benefits of adding glucagon in bi-
hormonal closed-loop systems to further reduce the
residual risk of hypoglycaemia with single-hormone
closed-loop systems or to allow more aggressive insulin
dosing and use glucagon to counteract a potential insulin
overdose [22]. The first study to evaluate the short-term
outpatient use of a bi-hormonal closed-loop system in
adults with type 1 diabetes applying more aggressive
insulin dosing showed lower mean glucose level and
hypoglycaemia risk during the 5-day study period [23].
Similar glycaemic benefits using bi-hormonal closed-loop
systems were observed in pre-adolescent children in a
Fig. 1 a A closed-loop system comprising a glucose sensor (black rectangle on the left-hand side of the abdomen), an insulin pump (device in the
pocket), and a mobile-sized device containing the control algorithm (in patient’s hand). Each component communicates with the other wirelessly
(adapted from Hovorka [32]). b The closed-loop system mimics the physiological feedback normally provided by the pancreatic beta cell
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diabetes camp setting [24]. Head-to-head comparison be-
tween single-hormone and bi-hormonal non-aggressive
closed-loop systems showed no significant difference in
the proportion of time in the glucose target range; how-
ever, fewer hypoglycaemic events occurred with the bi-
hormonal system [25]. In contrast to single-hormone
studies, however, bi-hormonal closed-loop systems have
not been evaluated during free-living settings over ex-
tended periods. The addition of glucagon imposes further
demands and complexity in daily life application and is
currently limited by the need to reconstitute glucagon
daily and the requirement of a second pump. Ongoing re-
search aims to address these issues.
Towards commercialisation
The MiniMed® 670G pump (Medtronic, Northridge,
CA), recently approved by the FDA, is a single hormone
hybrid closed-loop system with the control algorithm in-
tegrated in the insulin pump (Fig. 2). The pump was
evaluated in a pivotal clinical trial to assess safety; how-
ever, due to the non-randomised study design and lack
of a control arm, statements pertaining to its efficacy are
limited [18]. The closed-loop system was used day-and-
night for 3 months by 94 adults and 30 adolescents. No
episodes of severe hypoglycaemia or ketoacidosis were
observed. Four serious adverse events, none device-
related, were reported.
Other device companies are developing similar single-
hormone hybrid closed-loop systems. These include the
Bigfoot Smartloop™ system and the Omnipod Artificial
Pancreas™ system, both of which are undergoing pilot
clinical evaluations (NCT02849288 and NCT02897557,
respectively). In addition, commercialisation of a bi-hormonal
closed-loop system in Europe is currently being planned
with the proposed date of approval in 2017 [26].
Indication for closed-loop in clinical practice
Criteria for application of closed-loop in clinical practice
are yet to be refined. Evidence is being collected in large
randomised clinical trials to justify the use of the
technology in a wide range population to funders and
healthcare professionals [16, 19, 21, 27], as well as eluci-
dating its glycaemia-related and psychosocial impacts.
Pathways range from using closed-loop systems in lieu
of sensor-augmented pump therapy, to application of
closed-loop systems immediately post-presentation of
type 1 diabetes if a decline in residual C-peptide secre-
tion could be slowed down. In the longer term, the
trend in increasing use of insulin pump therapy could
be accelerated and a greater proportion of those utilis-
ing multiple daily injection may opt for closed-loop
systems. Unwillingness or intolerance to wear a
continuous glucose monitoring and/or insulin pump,
excludes closed-loop use in clinical practice.
Expectations and implications in clinical practice
Although commercialisation and clinical availability of
closed-loop systems is imminent, the implications of
user acceptance and interaction with this novel technol-
ogy are yet to be fully understood. Based on our exten-
sive experience of home studies, amounting to total
closed-loop operation of 3380 days, or 9.3 years, in
populations such as children, adolescents, pregnancy, and
well- and suboptimally controlled adults, we found that
users may have different expectations of closed-loop
technology and its role in their care. A ‘one size fits all’
may not be the appropriate model, as different user
demands need to be catered for. Some participants
suggested having a more simplified or ‘hands-off ’ ap-
proach, which includes minimal input for prandial insulin
boluses to reduce the burden of self-management. Others
Fig. 2 Hybrid closed-loop system comprising fourth generation Enlite
3 glucose sensor, MiniMed® 670G insulin pump, and an integrated
proportional-integral-derivative algorithm with insulin feedback
(Medtronic, Northridge, CA) (courtesy of Medtronic)
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wished to be more involved in their interaction with the
closed-loop system, such as being able to ‘adjust’ the con-
trol algorithm to their individual needs, i.e. personalisation
of their glucose target range based on time of day, state of
health or physical activity. The message from our experi-
ence is that the designers of closed-loop systems may need
to consider both simplified and sophisticated user-system
interaction, while accounting for individual needs and
expectations.
Current research prototypes and upcoming commer-
cialised systems require on-going user input and inter-
action. Hybrid systems require user-triggering of insulin
boluses for meals that may not match users’ initial ex-
pectations of an ‘artificial pancreas’, thus emphasising
the ongoing need for education and training of this
novel technology. In previously sensor-naïve individuals
transitioning to closed-loop therapy, the availability and
use of continuous glucose monitoring may introduce
additional need for training by educators. For example,
the sensor alarms, miscalibration and overreaction to
glucose trends can negatively affect user experience,
adherence and outcomes, if not addressed earlier on.
The immediate impact on currently available structured
education programmes [28] is currently unknown and
needs further evaluation. The focus of these programmes
may therefore need to account for different strategies
and approaches in individuals using closed-loop systems,
during meals and exercise, for example. The emphasis
on diabetes self-management still needs to be main-
tained in the event of a closed-loop system not being op-
erational due to unavailable sensor data, for example,
and the role for technical support, be it from the manu-
facturer or healthcare providers, needs to be delineated.
Outlook
It is anticipated that future closed-loop systems may
involve the use of non-calibrated sensors which may
further reduce device burden [29]. The advent of faster
insulins [30] and availability of stable glucagon [31] may
enhance the performance of single-hormone and bi-
hormonal closed-loop systems, respectively. Although it
is expected that no significant added expenses apart
from those related to continuous glucose monitoring
may be conferred on the user, longer studies evaluating
long-term biomedical and psychosocial outcomes, as
well as cost-effectiveness, are needed to justify and pro-
vide wider reimbursements for all users.
Conclusions
Although the ideal situation would be a biological cure for
type 1 diabetes, where damaged beta-cells could be re-
placed with healthy ones and be viable, the interim but
fast innovating role of the artificial pancreas might be to
act as a ‘bridge’ until that cure is found. The rapid
progress from ‘bench to bedside’ in the past decade has
made the artificial pancreas a reality, and may hopefully
lead towards better care in the management of people
with type 1 diabetes in the near future.
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